Patent 5189064 Issued on February 23, 1993. Estimated Expiration Date: May 14, 2010. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
Cocaine addiction is treated by administration of an endorphinase or enkephalinase inhibitor, and optionally, a dopamine precursor, or a serotonin precursor, a GABA precursor, or an endorphin or enkephalin releaser. These components promote restoration of normal neurotransmitter function and are non-addictive. Use of the dopamine precursors L-phenylalanine or L-tyrosine, the enkephalinase inhibitor D-phenylalanine and/or the serotonin precursor L-tryptophan is especially preferred.
Other References
Bain, et al.; Life Sciences 40:1119-1125 (1986); Naloxone Attenuation of the Effect of Cocaine on Rewarding Brain Stimulation
Schwartz, et al.; Neuropharmacology 17:665-685 (1978); Modulation of Receptor Mechanisms in the CNS:Hyper and Hyposensitivity to Catecholamines
Letter to the Editor; J. Pharm. Pharmac., 24:905-06 (1972); Dopamine turnover in the Corpus Striatum and the Limbic System After Treatment with Neuroleptic and Anti-acetylcholine Drugs
Reggiani, et al.; Substance and Alcohol Actions/Misuse; 1:151-58 (1980); Role of Dopaminergic-Enkephalinergic Interactions in the Neurochemical Effects of Ethanol
Mello, et al.; Science; 245:859-862 (1989); Buprenorphine Supresses Cocaine Self-Administration by Rhesus Monkeys
Misra, et al.; Pain; 28:129-138 (1987); Stereospecific Potentiation of Opiate Analgesia by Cocaine: Predominant Role of Noradrenaline
Hughes, et al.; Nature; 258:577-579 (1975); Identification of Two Related Pentapeptides from the Brain with Potent Opiate Against Activity
Li and Chung; Proc. Nat. Acad. Sci.; 73:1145-1148 (1976); Isolation and Structure of an Untriakontapeptide with Opiate Activity from Camel Pituitary Glands
Hammer; Dept. of Anatomy & Reprod. Biol., Univ. Hawaii School of Medicine; Cocaine Altera Opiate Receptor Binding in Critical Brain Reward Regions (1976)
Tennant & Sagherian, Double-Blind Comparison of Amantidine and Bromocriptine for Ambulatory Withdrawal from Cocaine Dependence, Arch. Intern. Med., 147:109-112, (Jan. 1987)
Rosen, et al., Clinical Trial of Carbidopa Combination for Cocaine Abuse, Am. J. Psychiatry, 143:1493 (Nov. 1986)
Reith, et al., Sodium-Independent Binding of 3 H Cocaine in Mouse Striatum is Serotonin Related, Brain Research, 342(1): 145-148 (1985)
Moir & Eccleston, The Effects of Precursos Loding in the Cerebral Metabolism of 5-Hydroxyindoles, J. Neurochem., 15:1093-1108 (1968)
Biggio, et al., Stimulation of Dopamine Synthesis in Caudate Nucleus by Intrastriatial Enkephalins and Antagonism by Naloxone, Science, 200:552-54 (May 1978)
Clouet, A Biochemical and Neurophysicalogical Comparison of Opioids and Antipsychotics, Annals New York Acad. of Sci., 398:130-137 (1982)
Dackis, et al., Bromocriptine Treatment for Cocaine Abuse: The Dopamine Depletion Hypothesis, Int'l. J. Psychiatry in Med., 15(2): 125-135 (1985)
Dackis, et al., New Concepts in Cocaine Addiction: The Dopamine Depletion Hypothesis, Science and Behavioral Reviews, 9:469-477 (1985)
Clouet, et al., Catecholamine Bisynthesis in Brains of Rats Treated with Morphine, Science, 168:854-855 (1970)
Gold, et al., New Insights and Treatments: Opiates Withdrawal and Cocaine Addiction, Clinical Therapeutics, 7(1): 6-21 (1984)
Verebey, et al., in Psychopharmacology of Cocaine: Behavior Neurophysiology, Neurochemistry and Proposed Treatment, Psychopharmacology: Impact on Clinical Psychiatry, 219-245, (1985)
Rosecran, Abstract, VII World Congress of Psychiatry, Vienna, Australia (1985)
Schwartz, et al., Fourth World Congress on Biological Psychiatry 418, No. 600.2 (1985)
Gessa, et al. 4th World Congress on Biological Psychiatry, 459 No. 620.10 (1985)
Mindell, Earl Mindell's Shaping up with Vitamins, pp. 162-163; 172-173 (1985)
May 14, 2010. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
